The Synergist runs programmes aimed at solving challenges which others ignore or have been unable to resolve. Our approach is a bit different. We’re not issue experts. We focus primarily on bringing the most important stakeholders together and building shared value, rather than trying to do it all ourselves. Given the complexity of the world we live in and the challenges we face, we’re convinced there is no better way.
The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed in collaboration with The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework. PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility. Stakeholders include patients and patient organizations across diverse areas of health and industry. We also intend to invite regulators, payers and other professional organizations to the global group to ensure diversity of perspectives.
GDPR and data protection, how this applies to trials, registries, big data and patient organisations data
13 Aug 2019 Other
WORKSHOP 1 How to engage patients in early development and preclinical phases of medicines development
23 Sep 2019
23 Sep 2019 Framework/guidance